UBS Group’s SpyGlass Pharma SGP Stock Holding History

UBS Group’s Portfolio SGP Stock Details SGP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$177K	Buy	7,945 +7,490	+1,646%	+$162K	﹤0.01%	6865
2026 Q1	$11.8K	Buy	+455	New	+$12.2K	﹤0.01%	8284

Other funds holding SGP

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

UBS Group's SGP Position: Q2 2026 in Review

UBS Group increased its SpyGlass Pharma (SGP) stake by 1,646% in Q2 2026, buying an estimated $162K and bringing the position to 7,945 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #6865.

UBS Group first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

UBS Group held 7,945 shares of SpyGlass Pharma worth $177K as of Q2 2026.
UBS Group bought 7,490 SpyGlass Pharma shares in Q2 2026, an estimated $162K.
SpyGlass Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6865 holding.
UBS Group first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.